RRA
GLUE icon

Round Rock Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

Round Rock Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$901K Hold
37,229
– – 0.12% 140
2026
Q1 		$612K Buy
+37,229
New +$712K 0.09% 174

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Round Rock Advisors's GLUE Position: Q2 2026 in Review

Round Rock Advisors held its Monte Rosa Therapeutics (GLUE) position steady in Q2 2026 at 37,229 shares worth $901K. The position accounts for 0.12% of the portfolio, ranked #140.

Round Rock Advisors first reported a position in GLUE in Q1 2026 and has held it in 2 quarters since. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Round Rock Advisors held 37,229 shares of Monte Rosa Therapeutics worth $901K as of Q2 2026.
  • Round Rock Advisors left its Monte Rosa Therapeutics share count unchanged in Q2 2026.
  • Monte Rosa Therapeutics made up 0.12% of Round Rock Advisors's portfolio in Q2 2026, its #140 holding.
  • Round Rock Advisors first reported a position in Monte Rosa Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Round Rock Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.